Literature DB >> 21571026

Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States.

Xin Wang1, Amanda Cohn, Maurizio Comanducci, Lubomira Andrew, Xin Zhao, Jessica R MacNeil, Susanna Schmink, Alessandro Muzzi, Stefania Bambini, Rino Rappuoli, Mariagrazia Pizza, Ellen Murphy, Susan K Hoiseth, Kathrin U Jansen, Annaliesa S Anderson, Lee H Harrison, Thomas A Clark, Nancy E Messonnier, Leonard W Mayer.   

Abstract

Neisseria meningitidis (Nm) serogroups B, C and Y are the major causes of meningococcal diseases in the United States. NmB accounts for ∼1/3 of the disease but no licensed vaccine is yet available. Two candidate vaccines are being developed specifically to target NmB, but may also provide protection against other serogroups. To assess the potential impact of these vaccines on NmB and other serogroups causing disease in the US, we determined the prevalence, genetic diversity and epidemiological characteristics of three candidate antigen genes in Nm isolates collected through Active Bacterial Core surveillance (ABCs), a population-based active surveillance program. fHbp was detected in all NmB, NmY and NmW135 isolates. Eleven NmC isolates contain fHbp with a single base-pair deletion creating a frame shift in the C-terminal region. Among NmB, 59% were FHbp subfamily/variant B/v1 and 41% A/v2-3. Among NmC and NmY, 39% and 3% were B/v1, respectively. nadA was detected in 39% of NmB, 61% of NmC and 4% of NmY. Among isolates tested, nhbA was present in all NmB and 96% of non-B. For the subset of strains sequenced for NadA and NhbA, pairwise identity was greater than 93% and 78%, respectively. The proportion of FHbp subfamily/variant was different between ABCs site and year, but no linear temporal trend was observed. Although assessment of the vaccine coverage also requires understanding of the antigen expression and the ability to induce bactericidal activity, our finding that all isolates contain one or more antigen genes suggests these candidate vaccines may protect against multiple Nm serogroups. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571026     DOI: 10.1016/j.vaccine.2011.04.092

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  49 in total

Review 1.  Neuro-intensive care of patients with acute CNS infections.

Authors:  J David Beckham; Kenneth L Tyler
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.

Authors:  Monica Konar; Rolando Pajon; Peter T Beernink
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

3.  Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Authors:  Massimiliano Biagini; Marco Spinsanti; Gabriella De Angelis; Sara Tomei; Ilaria Ferlenghi; Maria Scarselli; Fabio Rigat; Nicola Messuti; Alessia Biolchi; Alessandro Muzzi; Giulia Anderloni; Brunella Brunelli; Elena Cartocci; Francesca Buricchi; Chiara Tani; Maria Stella; Monica Moschioni; Elena Del Tordello; Annalisa Colaprico; Silvana Savino; Marzia M Giuliani; Isabel Delany; Mariagrazia Pizza; Paolo Costantino; Nathalie Norais; Rino Rappuoli; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

4.  Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.

Authors:  Heidi M Soeters; Melissa Whaley; Nicole Alexander-Scott; Koren V Kanadanian; Jessica R MacNeil; Stacey W Martin; Lucy A McNamara; Kenneth Sicard; Cynthia Vanner; Jeni Vuong; Xin Wang; Utpala Bandy; Manisha Patel
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

5.  Meningococcal carriage among a university student population - United States, 2015.

Authors:  Lucy Breakwell; Melissa Whaley; Unab I Khan; Utpala Bandy; Nicole Alexander-Scott; Lynn Dupont; Cindy Vanner; How-Yi Chang; Jeni T Vuong; Stacey Martin; Jessica R MacNeil; Xin Wang; Sarah A Meyer
Journal:  Vaccine       Date:  2017-11-26       Impact factor: 3.641

6.  Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody.

Authors:  Enrico Malito; Marco Biancucci; Agnese Faleri; Ilaria Ferlenghi; Maria Scarselli; Giulietta Maruggi; Paola Lo Surdo; Daniele Veggi; Alessia Liguori; Laura Santini; Isabella Bertoldi; Roberto Petracca; Sara Marchi; Giacomo Romagnoli; Elena Cartocci; Irene Vercellino; Silvana Savino; Glen Spraggon; Nathalie Norais; Mariagrazia Pizza; Rino Rappuoli; Vega Masignani; Matthew James Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

7.  Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.

Authors:  Serena Giuntini; Eduardo Lujan; Malick M Gibani; Christina Dold; Christine S Rollier; Andrew J Pollard; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

8.  Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.

Authors:  Eduardo Lujan; Elizabeth Partridge; Serena Giuntini; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

9.  First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.

Authors:  Lucy A McNamara; Alice M Shumate; Peter Johnsen; Jessica R MacNeil; Manisha Patel; Tina Bhavsar; Amanda C Cohn; Jill Dinitz-Sklar; Jonathan Duffy; Janet Finnie; Denise Garon; Robert Hary; Fang Hu; Hajime Kamiya; Hye-Joo Kim; John Kolligian; Janet Neglia; Judith Oakley; Jacqueline Wagner; Kathy Wagner; Xin Wang; Yon Yu; Barbara Montana; Christina Tan; Robin Izzo; Thomas A Clark
Journal:  Pediatrics       Date:  2015-05       Impact factor: 7.124

Review 10.  The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Authors:  Gary W Zlotnick; Thomas R Jones; Paul Liberator; Li Hao; Shannon Harris; Lisa K McNeil; Duzhang Zhu; John Perez; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.